By focusing on interventions that target the biology of aging rather than treating individual age-related diseases, geroscience offers not just a revolutionary path to living healthier, longer, but also the potential for unparalleled economic returns for biomedical research and development.
As a result, increasing healthspan can yield significant economic benefits by reducing healthcare costs, improving voluntary labor productivity, and reducing the strain facing unpaid caregivers.
Still, the prospect of living healthier, longer raises broad-reaching, cross-sector concerns—from possible burdens on our pension systems to the ethics of (in)equitable access to novel therapeutics—that could help or hinder personal wellness and public health.
To explore how biomedical research and social planning can advance mindfully together, AFAR brings together perspectives in biology, bioethics, economics, and innovation for a timely fireside chat.
Featuring in Conversation:
Brian Bergstein
Deputy Managing Editor, IDEAS
The Boston Globe
Thomas A. Rando, MD, PhD
AFAR President; Director, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Biology at UCLA; Co-Founder, Stanford Center on Longevity
Raiany Romanni, PhD
AFAR Scholar-in-Residence; Author, Silver Linings: The Ethics and Economics of Redesigning Aging (working title, Harvard University Press, 2026).
The free webinar will also highlight fresh economic findings on the ROI of R&D in geroscience and gerotherapeutics, developed by Dr. Romanni with a team from Harvard, the Abundance Institute, and the University of Southern Carolina and with input from interviews with 102 aging researchers and longevity scientists.
